KORELASI JUMLAH MONOSIT DENGAN KADAR C-REACTIVE PROTEIN PADA PENDERITA TUBERKULOSIS
Isi Artikel Utama
Abstrak
Tuberculosis (TB) caused by Mycobacterium tuberculosis (MTB) is still a public health problem throughout the world, including in Indonesia. Monocytes play a role in cellular reactions against MTB bacteria and are considered a marker of active TB spread. C-Reactive Protein (CRP) examination is very useful for diagnosing inflammation or infectious diseases. This study aimed to determine the correlation between monocyte counts and CRP levels in TB patients in North Putussibau. This research was observational analytic with cross-sectional approach and the sampling technique was accidental nonprobability sampling. The sample was TB patients in North Putussibau who were undergoing treatment for 0, 2, and 6 months in 2022, resulting in 36 patients. Monocyte counts were examined using the fluorescence method and CRP levels were examined using the latex agglutination method. At 0 months of treatment, the monocyte count was obtained with an average of 1.096.88cells/µL and average CRP level of 55.13mg/L, at 2 months of treatment the average monocyte count was 742.31 cells/µL and CRP levels were obtained an average of 10.62mg/L, and after 6 months of treatment an average monocyte count was 414.29cells/µL and an average CRP level of 0mg/L. The Kendall's Tau-b test showed a significant value 0.000 (<0.05), which means there was a significant correlation between the number of monocytes and CRP levels in TB patients with a correlation coefficient 0.645 which shows the strength of strong relationship. This shows that the decrease in the number of monocytes and CRP levels is in line with the length of the TB treatment period.
Rincian Artikel
Referensi
T. N. Susilawati and R. Larasati, “A recent update of the diagnostic methods for tuberculosis and their applicability in Indonesia: a narrative review,” Medical Journal of Indonesia, vol. 28, no. 3, pp. 284–291, 2019.
R. Gopalaswamy, S. Shanmugam, R. Mondal, and S. Subbian, “Of tuberculosis and non-tuberculous mycobacterial infections - a comparative analysis of epidemiology, diagnosis and treatment,” J Biomed Sci, vol. 27, no. 1, p. 74, Jun. 2020, doi: 10.1186/s12929-020-00667-6.
C. Bussi and M. G. Gutierrez, “Mycobacterium tuberculosis infection of host cells in space and time,” FEMS Microbiol Rev, vol. 43, no. 4, p. 341—361, Jul. 2019, doi: 10.1093/femsre/fuz006.
A. D. I. Hasanuddin, N. Roswita, and I. V. Amu, “Immune Response toward Mycobacterium Tuberculosis Infection,” Green Medical Journal, vol. 2, no. 2, pp. 77–87, 2020.
M. A. Behr, P. H. Edelstein, and L. Ramakrishnan, “Revisiting the timetable of tuberculosis,” BMJ, vol. 362, p. k2738, Aug. 2018, doi: 10.1136/bmj.k2738.
T. Togun, B. Kampmann, N. G. Stoker, and M. Lipman, “Anticipating the impact of the COVID-19 pandemic on TB patients and TB control programmes,” Ann Clin Microbiol Antimicrob, vol. 19, no. 1, p. 21, May 2020, doi: 10.1186/s12941-020-00363-1.
T. Lestari et al., “Impacts of tuberculosis services strengthening and the COVID-19 pandemic on case detection and treatment outcomes in Mimika District, Papua, Indonesia: 2014–2021,” PLOS global public health, vol. 2, no. 9, p. e0001114, 2022.
Y. Faturahman and A. Purwanto, “ITGBM Pembentukan Kader Pengawas Minum Obat (PMO) Pada Penderita Tuberculosis,” Jurnal Pengabdian Siliwangi, vol. 4, no. 1, pp. 8–12, 2018.
A. S. W. Ningsih, A. M. Ramadhan, and D. Rahmawati, “Kajian Literatur Pengobatan Tuberkulosis Paru dan Efek Samping Obat Antituberkulosis di Indonesia,” in Proceeding of Mulawarman Pharmaceuticals Conferences, 2022, pp. 231–241.
M. de Martino, L. Lodi, L. Galli, and E. Chiappini, “Immune Response to Mycobacterium tuberculosis: A Narrative Review,” Front Pediatr, vol. 7, p. 350, 2019, doi: 10.3389/fped.2019.00350.
P. Sampath, K. Moideen, U. D. Ranganathan, and R. Bethunaickan, “Monocyte Subsets: Phenotypes and Function in Tuberculosis Infection,” Front Immunol, vol. 9, p. 1726, 2018, doi: 10.3389/fimmu.2018.01726.
A. Saripalli and J. Ramapuram, “C-Reactive Protein as a Screening Test for Tuberculosis in People Living with HIV in Southern India: A Cross-Sectional, Observational Study,” J Clin Med, vol. 11, no. 13, p. 3566, Jun. 2022, doi: 10.3390/jcm11133566.
N. R. Sproston and J. J. Ashworth, “Role of C-Reactive Protein at Sites of Inflammation and Infection,” Front Immunol, vol. 9, p. 754, 2018, doi: 10.3389/fimmu.2018.00754.
M. Humayun, J. Chirenda, W. Ye, I. Mukeredzi, H. A. Mujuru, and Z. Yang, “Effect of Gender on Clinical Presentation of Tuberculosis (TB) and Age-Specific Risk of TB, and TB-Human Immunodeficiency Virus Coinfection,” Open Forum Infect Dis, vol. 9, no. 10, p. ofac512, Oct. 2022, doi: 10.1093/ofid/ofac512.
A. D. Tyastuti, “Hubungan Antara Kadar C-Reactive Protein Dengan Derajat Keparahan COVID-19 Studi Observasional Analitik Pada Pasien Rawat Inap Di RS Islam Sultan Agung Semarang,” Universitas Islam Sultan Agung Semarang, Semarang, 2022.
R. D. Pratiwi, D. Pramono, and J. Junaedi, “Socio-economic and environmental risk factors of tuberculosis in wonosobo, central Java, Indonesia,” Jurnal Kesehatan Masyarakat, vol. 16, no. 1, pp. 61–70, 2020.
P. Caraux-Paz, S. Diamantis, B. de Wazières, and S. Gallien, “Tuberculosis in the Elderly,” J Clin Med, vol. 10, no. 24, p. 5888, Dec. 2021, doi: 10.3390/jcm10245888.
M. S. D. Wijaya, M. F. J. Mantik, and N. H. Rampengan, “Faktor Risiko Tuberkulosis pada Anak,” e-CliniC, vol. 9, no. 1, 2021.
S.-J. Li et al., “Population aging and trends of pulmonary tuberculosis incidence in the elderly,” BMC Infect Dis, vol. 21, no. 1, p. 302, Mar. 2021, doi: 10.1186/s12879-021-05994-z.
S. Kany, J. T. Vollrath, and B. Relja, “Cytokines in Inflammatory Disease,” Int J Mol Sci, vol. 20, no. 23, p. E6008, Nov. 2019, doi: 10.3390/ijms20236008.
S. D. Ergiana, D. P. K. Wardani, T. A. Sudarsono, and A. Mulyanto, “Hubungan Kadar C-Reactive Protein dengan Jumlah Leukosit Penderita Tuberkulosis Paru pada Fase Pengobatan 0 dan 2 Bulan di BKPM Purwokerto,” Jurnal Surya Medika (JSM), vol. 8, no. 2, pp. 62–77, 2022.
C. N. Marbun, “Gambaran Jumlah Monosit Pada Pasien Tuberkulosis Paru yang Mendapat Terapi Obat Anti Tuberkulosis (OAT) di RS Khusus Paru Provinsi Sumatera Selatan Tahun 2019,” Poltekkes Kemenkes Palembang, Palembang, 2019.
G. S. Nugraha, Y. R. Romli, and N. P. Sari, “Hubungan Faktor Pelaksanaan Tugas Pengawas Menelan Obat (Pmo) Dengan Kejadian Drop Out (Do) Pengobatan Tuberculosis (TB),” Healthcare Nursing Journal, vol. 1, no. 2, pp. 12–17, 2019.
W. H. Cahyati and T. Maelani, “Karakteristik penderita, efek samping obat dan putus berobat tuberkulosis paru,” HIGEIA (Journal Of Public Health Research And Development), vol. 3, no. 4, pp. 625–634, 2019.
N. M. Mertaniasih, Buku Ajar Tuberkulosis Diagnostik Mikrobiologis. Surabaya: Airlangga University Press, 2019.
A. Anisah, D. W. Sumekar, and E. Budiarti, “Demografi dan Komorbid dengan Kejadian Tuberkulosis Resisten Obat (TB RO),” Jurnal Ilmiah Kesehatan Sandi Husada, vol. 10, no. 2, pp. 568–574, 2021.
R. Nabatanzi, S. Cose, M. Joloba, S. R. Jones, and D. Nakanjako, “Effects of HIV infection and ART on phenotype and function of circulating monocytes, natural killer, and innate lymphoid cells,” AIDS Res Ther, vol. 15, no. 1, p. 7, Mar. 2018, doi: 10.1186/s12981-018-0194-y.
E. Nikitina, I. Larionova, E. Choinzonov, and J. Kzhyshkowska, “Monocytes and Macrophages as Viral Targets and Reservoirs,” Int J Mol Sci, vol. 19, no. 9, p. E2821, Sep. 2018, doi: 10.3390/ijms19092821.